My impression at the time and still is that because the timelines overlap so closely is that the extra 10 patients are not to difficult to get. The process of pulling together the data I would think is easy to predict. My guess is that the relaxed criteria allowed patients that did not qualify before, now can so it is not hard to get the trial enrolled at 50. The mood about the extra 10 patients in the CC did not seem to me to be presented as a disaster, and might actually be good because the data may be much more representative of the HIV market.
News 
Market Data 
Discover 
